Whitehawk Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Whitehawk Therapeutics
WHWK Stock   2.81  0.03  1.08%   
Analyzing historical trends in various income statement and balance sheet accounts from Whitehawk Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Whitehawk Therapeutics' valuation are summarized below:
Gross Profit
-73.5 M
Profit Margin
(1.09)
Market Capitalization
131 M
Enterprise Value Revenue
3.4826
Revenue
14.4 M
There are currently one hundred twenty fundamental gauges for Whitehawk Therapeutics that can be evaluated and compared over time across peers. We recommend to confirm Whitehawk Therapeutics' prevalent fundamental drivers against the all of the trends between 2010 and 2026. The value of Market Cap is estimated to slide to about 60.3 M. Enterprise Value is expected to rise to about (7 M) this year

Whitehawk Therapeutics Total Revenue

15.03 Million

Check Whitehawk Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Whitehawk Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 117.5 K, Interest Expense of 131.7 K or Selling General Administrative of 26.4 M, as well as many indicators such as Price To Sales Ratio of 3.59, Dividend Yield of 0.0165 or PTB Ratio of 1.54. Whitehawk financial statements analysis is a perfect complement when working with Whitehawk Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Whitehawk Stock
Check out the analysis of Whitehawk Therapeutics Correlation against competitors.
For more information on how to buy Whitehawk Stock please use our How to buy in Whitehawk Stock guide.

Whitehawk Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets106.4 M80.9 M54 M
Slightly volatile
Short and Long Term Debt Total712.2 K749.7 K5.9 M
Slightly volatile
Other Current Liabilities16.7 M16.8 M14.8 M
Slightly volatile
Total Current Liabilities17.8 M15.4 M23.4 M
Slightly volatile
Property Plant And Equipment Net9.2 M8.8 M2.2 M
Slightly volatile
Accounts Payable4.3 M2.5 M3.5 M
Pretty Stable
Cash55 M33 M31.3 M
Slightly volatile
Non Current Assets Total10.9 M10.4 M3.1 M
Slightly volatile
Non Currrent Assets Other1.7 M1.6 M796.5 K
Slightly volatile
Cash And Short Term Investments91.3 M54.3 M46.3 M
Slightly volatile
Common Stock Shares Outstanding20.4 M31.1 M13.8 M
Slightly volatile
Liabilities And Stockholders Equity106.4 M80.9 M54 M
Slightly volatile
Non Current Liabilities Total837.9 K882 K1.1 M
Slightly volatile
Other Current Assets2.4 M3.3 M1.1 M
Slightly volatile
Other Stockholder Equity264 M442.9 M136.9 M
Slightly volatile
Total Liabilities19.9 M16.1 M24.5 M
Slightly volatile
Total Current Assets101.2 M70.5 M51.2 M
Slightly volatile
Short Term Debt229.1 K241.2 K5.6 M
Slightly volatile
Common Stock1.8 K2.3 K1.2 K
Slightly volatile
Long Term Debt881.6 K991.8 K1.1 M
Slightly volatile
Capital Lease Obligations988 K958 K452.2 K
Slightly volatile
Property Plant And Equipment Gross9.8 M9.3 M2.2 M
Slightly volatile
Short and Long Term Debt7.2 M8.1 M8.9 M
Slightly volatile
Capital Stock1.6 K1.8 K2 K
Slightly volatile
Non Current Liabilities Other164.4 K232.3 K133.6 K
Slightly volatile
Intangible Assets3 M3.4 M3.7 M
Slightly volatile

Whitehawk Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization117.5 K221.9 K60.8 K
Slightly volatile
Interest Expense131.7 K138.6 K188.5 K
Slightly volatile
Selling General Administrative26.4 M42.3 M13.5 M
Slightly volatile
Total Revenue15 M29.9 M7.9 M
Slightly volatile
Other Operating Expenses75.2 M107.5 M41.7 M
Slightly volatile
Research Development32.7 M58.7 M21.7 M
Slightly volatile
Cost Of Revenue34 M62.2 M22.4 M
Slightly volatile
Total Operating Expenses41.2 M45.3 M19.3 M
Slightly volatile
Income Tax Expense1.9 K2.3 K1.6 K
Slightly volatile
Interest Income2.8 M4.5 M1.2 M
Slightly volatile
Reconciled Depreciation139.7 K221.9 K63.9 K
Slightly volatile

Whitehawk Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation6.4 M12.5 M3.2 M
Slightly volatile
Depreciation117.5 K221.9 K60.8 K
Slightly volatile
Total Cash From Financing Activities111.2 K117 K17.5 M
Pretty Stable
End Period Cash Flow55 M33 M31.3 M
Slightly volatile
Begin Period Cash Flow59.7 M72.4 M33.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.593.7868.8349
Slightly volatile
Dividend Yield0.01650.01850.0202
Slightly volatile
Days Sales Outstanding15595.36132
Pretty Stable
Average Payables2.2 M2.5 M2.7 M
Slightly volatile
Stock Based Compensation To Revenue0.480.380.3358
Slightly volatile
Capex To Depreciation6.617.716.46
Pretty Stable
Inventory Turnover13.3911.716.5179
Slightly volatile
Days Of Inventory On Hand26.9832.2823.5415
Slightly volatile
Payables Turnover23.6622.537.8712
Slightly volatile
Sales General And Administrative To Revenue15.6214.877.1473
Slightly volatile
Research And Ddevelopement To Revenue2.152.2610.4026
Slightly volatile
Capex To Revenue0.05510.05730.0545
Slightly volatile
Cash Per Share1.491.573.2378
Pretty Stable
Days Payables Outstanding15.9316.7779.5601
Slightly volatile
Income Quality1.311.080.888
Slightly volatile
Intangibles To Total Assets0.01930.02170.0237
Slightly volatile
Current Ratio3.873.232.4623
Slightly volatile
Receivables Turnover3.33.963.5155
Slightly volatile
Capex Per Share0.03820.05510.0224
Slightly volatile
Revenue Per Share0.460.870.3357
Slightly volatile
Interest Debt Per Share0.03990.0420.7345
Slightly volatile
Debt To Assets0.01290.01360.3353
Slightly volatile
Operating Cycle177137143
Very volatile
Days Of Payables Outstanding15.9316.7779.5601
Slightly volatile
Ebt Per Ebit1.131.091.0274
Pretty Stable
Quick Ratio3.782.952.4021
Slightly volatile
Net Income Per E B T1.11.151.0148
Slightly volatile
Cash Ratio2.221.511.5292
Slightly volatile
Days Of Inventory Outstanding26.9832.2823.5415
Slightly volatile
Days Of Sales Outstanding15595.36132
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.820.920.9938
Slightly volatile
Fixed Asset Turnover3.723.918.9576
Pretty Stable
Debt Ratio0.01290.01360.3353
Slightly volatile
Price Sales Ratio3.593.7868.8349
Slightly volatile
Asset Turnover0.260.420.1498
Slightly volatile

Whitehawk Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap60.3 M63.5 M88.4 M
Pretty Stable

Whitehawk Fundamental Market Drivers

Forward Price Earnings2.661
Cash And Short Term Investments47.2 M

About Whitehawk Therapeutics Financial Statements

Whitehawk Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Whitehawk Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue29.9 M15 M
Cost Of Revenue62.2 M34 M
Stock Based Compensation To Revenue 0.38  0.48 
Sales General And Administrative To Revenue 14.87  15.62 
Research And Ddevelopement To Revenue 2.26  2.15 
Capex To Revenue 0.06  0.06 
Revenue Per Share 0.87  0.46 
Ebit Per Revenue(2.34)(2.45)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Whitehawk Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Whitehawk Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Whitehawk Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Whitehawk Therapeutics Stock:
How To Invest In Whitehawk
Details
Is Whitehawk Stock a good investment?
Details
What is Whitehawk Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Whitehawk Therapeutics Correlation against competitors.
For more information on how to buy Whitehawk Stock please use our How to buy in Whitehawk Stock guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Whitehawk Therapeutics. Anticipated expansion of Whitehawk directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Whitehawk Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(0.64)
Revenue Per Share
0.28
Quarterly Revenue Growth
0.335
Return On Assets
(0.54)
Return On Equity
(0.14)
Investors evaluate Whitehawk Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Whitehawk Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Whitehawk Therapeutics' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Whitehawk Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Whitehawk Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Whitehawk Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY